Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | FOLFIRINOX, gemcitabine + paclitaxel to enhance surgery outcomes for locally advanced PC

Rainer Fietkau • 6 Jun 2022
ASCO 2022
Gastrointestinal Cancer Pancreatic Cancer Folfirinox Gemcitabine Paclitaxel

Combined chemotherapy with FOLFIRINOX, gemcitabine and paclitaxel has previously been demonstrated to improve overall-survival (OS) in metastatic pancreatic cancer. Rainer Fietkau, MD, PhD, University Hospital Erlangen, Erlangen, Germany discusses utilizing this chemotherapy regimen to help avoid the development of distant metastases in patients with locally advanced disease during induction chemotherapy to enhance the benefit of surgery. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Rainer Fietkau

0:47
Remaining areas of unmet need for patients with locally advanced pancreatic cancer
Rainer Fietkau • 6 Jun 2022
2:25
CONKO-007: chemoradiotherapy increases rates of R0 resection in locally advanced pancreatic cancer
Rainer Fietkau • 6 Jun 2022

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals